Serial Salesman: Kailera CEO Ron Renaud has built and sold three biotechs, the last for $8.7 billion. “Companies get bought, they don’t get sold,” he says. But the obesity market’s frenzy could make Kailera a prime acquisition target.
Albie Colantonio for Forbes